Cytokines and endocrine system: Is it meaningful to monitor more than the thyroid gland?;ZYTOKINTHERAPIE UND ENDOKRINIUM: IST ES SINNVOLL, MEHR ALS DIE SCHILDDRUSE ZU UNTERSUCHEN?

Medizinische Klinik

Volumn 91, Issue 2, 1996, Pages 59-65

  Schuppert, Frank ^a   Müller Kunert, Ewald ^a   Stöcker, Winfried ^a   Bokemeyer, Carsten ^a   Schmoll, Hans Joachim ^a   Von Zur Mühlen, Alexander ^a   Rambusch, Erwin Gerhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSIS; DRUG EFFECT; ENDOCRINE SYSTEM; HUMAN; LEUKEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; PATIENT MONITORING; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID GLAND;

ADULT; AGED; AUTOANTIBODIES; DRUG MONITORING; FEMALE; HORMONES; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MIDDLE AGED; THYROID GLAND; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE;

EID: 0029887614     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Atkins, M B., J W. Mier, D. R Parkinson, J A Gould, E. M Berkman, M M Kaplan: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells New Engl J. Med 318 (1988), 1557-1563.
2. Atkins, M B., M M. Kaplan, P A. Demchak, S. Reichlin, J W. Mier Thyroid dysfunction after high-dose interleukin-2 therapy An update In; Scherbaum, W A., U Bogner, B Weinheimer, G. F. Bottazzo (eds): Autoimmune thyroiditis Approches towards its etiological differentiation Springer, Berlin - Heidelberg -New York 1991, p 271-281.
3. Atzpodien, J., K. Korfer, C R. Franks, H Poliwoda, H. Kirchner Home therapy with recombinant interleukin-2 and recombinant interferon-α2b in advanced human malignancies. Lancet 335 (1990), 1509-1511
4. Baudin, E , P Marcellin, M. Pouteau, N Colas-Linhart, J.-P. Le Floch, C Lemmomers. J.-P. Benhamou, B. Bok Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocr. 39 (1993), 657-661.
5. Bottazzo, G F., T. Hanafusa, R Pujol-Borell, M Feldmann, Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2 (1983), 1115-1118.
6. Chambrier, C , A Mercatello, E, Tognet, J. M Cottet-Emard, R Cohen, J Y Blay, M Favrot, T Philip, M Beylot. Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients J. biol Response Mod 9 (1990), 251-255
7. Chapman, R. M , S B Sutchffe, J S Malps' Male gonadal dvsfunction in Hodgin's disease J Amer med. Ass 245 (1989), 2496-2498.
8. Chlebowski, R T, D Heber Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 42 (1982), 2495-2498.
9. Conlon, K C., W J. Urba, J W Smith, R. G Steis, D. L, Longo, J W Clark: Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy Cancer 65 (1990), 2237-2242
10. Farkkila, A. M., M V Ivanainen, M, A Farkkila Disturbance of water and elctrolyte balance during high-dose interferon treatment. J Interferon Res. 10 (1990), 221-227
11. Fattovich G , C. Betterle, L Brollo, B Pedini, G Giustina, G. Realdi, A. Alberti A , A. Ruol Autoantibodies during alpha-interferon therapy for chronic hepatitis B J med Virol 34 (1991), 132-136
12. Fentimann, I S., F. R., Balkwill, B S Thomas, M J. Russel, I Todd, G F. Bottazzo: An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Europ. J. Cancer clin Oncol, 24 (1988), 1299-1303
13. Jones, G J , L M Itrr Safety and tolerance of interferon alpha-2a (Roferon®-A) in cancer patients. Cancer 57 (1986), 1709-1715
14. Lisker-Melman, M . A M. di Bisceglie, S J. Usala, B Weintraub, L M Murray, J H Hoofnagle Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 102 (1992), 2155-2160
15. Mayet, W J, G Hess, G Gerken, S. Rossol, R. Voth, M. Manns, K H. Meyer zum Buschenfelde: Treatment of chronic type B hepatitis with rerombinant alpha-interferon induces autoantibodies not specific for autoimmune chronie hepatitis Hepatology 10 (1989), 24-28.
16. Meikle, A W , J C Cardoso, J H Ward, M Woodward, W E Samlowskr Reduction of testosterone synthesis after high dose interleukin-2 therapy of metastatic cancer.J clin Endor Metab 73 (1991), 931-935.
17. Nikolai, T F Chapter 49 Thyrotoxicosis without hyperthytodism. In Ingbar, S H., L E Braverman (eds ). Werner's The Thyroid A fundamental AND clinical text B Lippincott Company Fifth Edition (1986) 1102-1103
18. Pichert, G , L M Jost, L Zobeli, B. Odermatt, G. Pedio, R. A Stahel. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Brit J. Cancer 62 (1990), 100-104.
19. Pichert, G , L M Jost, W Fierz, R. A Stahel. Clinical and immune modulatory effect of alternative weekly interleukin-2 and interferon alpha-2a in patieats with advanced renal cell carcinoma and melanoma. Brit J Cancer 63 (1991), 287-292.
20. Potlock, C. S Therapeutic approches to the treatment of hairy cell leukemia Semin Oncol. 13, Suppl 5 (1986), 55-59
21. Rambusch, E G, F Schuppert, S Olbrich, W. Stocker, H. Kirchner, J Atzpodren, H Poliwoda, A von zur Muhlen Influence of alpha interferon and interleukin-2 on the development of autoantibodies against the thyroid and other endocrine and non-endocrine organs in patients with malignant tumors Acta endocr 126, Suppl 4, (1992), 94.
22. Ronnblom, L E , G. V. Alm, K E Oberg. Autoimmunity after alpha-interferon therapy for malignent carcinoid tumors. Ann intern Med. 115 (1991), 178-183
23. Roosth, J , R B. Pollard. S L. Brown, W J. Meyer. Cortisol stimulation by recombinant interferon-α2. J. Neuroimmunol 12 (1986), 311-316
24. Rosenberg, S A., M. T Lotze, L M. Muul, A E. Chang, F. P. Avis, S Leitman, W. Marston Linehan, C N Robertson, R E Lee, J T. Rubin, C L Seipp, C G Simpson, D. E. White A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med. 316 (1987,) 889-897
25. Sabatim, M , B. Bovce, Th Aufdemorte, L, Bonewald, G R Mundy Infusion of recombinant human interleukins-1a and-1b cause hypercalcemia in mice Proc. nat Acad Sci. (Wash) 85 (1988), 5235-5239.
26. Saito, S, M Saito, P Ngan. R. Lanese, J Shanfeld, K. Davidovitch Effects of parathyroid hormone and cytokines on prostaglandin E synthesis and bone resoption by human peridontal ligament fibroblasts. Arch Oral Biol 35 (1990), 845-855
27. Saracco, G., A Touscoz, M Durazzo, F Rosina, E Donegani, L. Chiandussi, V Gallo, R. Petrino, A, G. De Micheli, A Solinas, A. Deplano, A Tocco, P A. Cossu, C Pintus, G Verine, M Rizzetto Autoantibodies and response to α-interferon in patients with chronic viral hepatitis. J. Hepatol. 11 (1990), 339-343
28. Sealzo, S , A Gengaro, G Boccoli, R Masciulli, G Gianella, G. Salvo, P Marolla, P Carlini,G Massimmi. E. E Holdener, U Testa, F. Calabresi, C Peschle: Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma, Europ. J. Cancer 26 (1990), 1152-1156
29. Schilsky, R. L., H S. Davidson, D Magid, S Daiter, H M. Golomb: Gonadal and sexual funktion in malt patients with hairy cell leukemia: Lack of adverse effects on recombinant a2 interferon treatment Cancer Treatin Rep 71 (1987), 179-181
30. Schwartzentruber, D J , D E White, M. H Zweig, B. D Weintraub, S A Rosenberg: Thyroid dysfunction associated with immunotherapy for patients with cancer Cancer 68 (1991), 2384-2390
31. Stocker, W: Rationelle Histochemie mit einer neuen Mikroanalyse methode Acta histochem. Suppl 31 (1985), 269-281
32. Tran, A , J -F. Quaranta, S. Benzaken, V Thiers, H. T Chau, P Hastier, D. Regnier, G Dreyfus, C Pradier, J -L Sadoul, X Hebuterne, P. Rampai High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy Hepatology 18 (1993). 253-257
33. van Liessum, P. A , P H D. de Mulder, E. J. M. Mattijssen, F H. M Corstens, D J. T. Wagener Hypothyroidism and goitre during interleukin-2 therapy without LAK cells. Lancet 1 (1989), 224.
34. Yan, S.-D , C.-C Huang: The role of tumor necrosis factor-alpha in bone resorption of cholesteatoma Amer. J Otolarengol. 12 (1991, 83-89.